Page last updated: 2024-08-21

quinazolines and Lung Adenocarcinoma

quinazolines has been researched along with Lung Adenocarcinoma in 275 studies

Research

Studies (275)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	260 (94.55)	24.3611
2020's	15 (5.45)	2.80

Authors

Authors	Studies
Chang, EJ; Hwang, S; Im, SS; Kim, J; Kim, JH; Lee, JH; Rho, JK; Shin, DM; Son, J	1
Cai, Y; Dong, Z; Sheng, Z; Wang, J	1
Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH	1
Li, B; Liao, H; Wang, Y; Zhou, B	1
Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M	1
Fujita, M; Igata, F; Ikeuchi, N; Ito, K; Masutani, K; Morita, D; Murayama, H; Nakamura, T; Nishida, Y; Oda, T; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T	1
Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T	1
Igai, H; Kamiyoshihara, M; Numajiri, K; Ohsawa, F	1
Lai, XY; Shi, YM; Zhou, MM	1
Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q	1
Chen, J; Chen, Q; Chen, Y; Jiang, C; Jiao, D; Liu, X; Liu, Y; Tang, X	1
Chuang, Q; Heng, W; Mingzhe, X; Shangli, C; You, C	1
Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D	1
Hata, AN; Klempner, SJ	1
Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X	1
Chen, DS; Jin, LL; Li, S; Wang, YL; Wu, ZZ; Xiao, M; Zhao, X	1
Liu, Q; Wu, L; Zhang, S	1
Ji, YX; Mu, XY; Sun, L; Zhang, L	1
Fan, Y; Han, N; Lu, H; Qin, J	1
Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X	1
Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L	1
Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M	1
Chong, IW; Chou, SH; Hsu, JS; Huang, MS; Hung, JY; Lee, JY; Liu, TC; Tsai, MJ; Wu, KL; Yang, CJ	1
Beadling, C; Corless, CL; Gay, ND; Neff, T; Tolba, K; Wang, Y; Warrick, A	1
Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L	1
Atallah, JP; Ibrahim, U; Saqib, A	1
Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY	1
Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T	1
Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y	1
Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z	1
Arata, S; Ohba, M; Ohmori, T; Yamaoka, T	1
Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y	1
Ch'ng, C; Chia, S; Gelmon, K; Ho, C; Ho, J; Ionescu, D; Jones, MR; Jones, SJM; Laskin, J; Leelakumari, S; Lim, H; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Ng, T; Pleasance, E; Reisle, C; Renouf, DJ; Schaeffer, DF; Shen, Y; Yip, S; Zhao, C; Zhao, Y; Zhong, E	1
Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL	1
Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ	1
Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A	1
Cheema, PK; Doherty, M; Tsao, MS	1
Fang, YF; Hsu, PC; Kao, KC; Li, SH; Liu, CY; Tseng, LC; Wang, CC; Yang, CT	1
Fukumoto, S; Harada, M; Kiuchi, S; Oizumi, S; Watanabe, M; Yamada, N; Yokouchi, H	1
Chong, IW; Hsu, JF; Huang, MS; Hung, JY; Lee, MH; Liu, TC; Tsai, MJ; Tsai, YC; Tsai, YM; Yang, CJ	1
Akizuki, R; Endo, S; Ikari, A; Maruhashi, R; Matsunaga, T; Sakai, H; Sato, T; Yamaguchi, M; Yamazaki, Y	1
Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V	1
Chan, RT	1
Han, R; He, Y; Jiao, L; Li, L; Wang, Y; Zheng, J	1
Cao, J; Hu, J; Lv, W; Lv, X; Wang, L; Xia, P	1
Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y	1
Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H	1
Chai, Y; Wu, Y; Yao, Y; Zhu, Z	1
Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T	1
Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Zhou, J	1
Gu, J; Jin, Y; Liang, X; Liu, T; Ma, H; Ma, X; Tao, J; Yang, T	1
Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J	1
Cui, J; Li, T; Li, Y; Su, D; Zhang, Y	1
Li, J; Li, Y; Pan, W; Yang, M; Zhang, L; Zhang, N; Zhu, H	1
Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y	1
Ikeuchi, T; Ishikawa, S; Tokuyasu, H	1
Chen, J; Wang, J	1
Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J	1
Guo, C; Li, R; Wu, K	1
Guan, Y; Guo, H; Li, Y; Shi, J; Song, Z; Yao, M; Zhang, X	1
Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y	1
Ando, C; Hara, N; Hirabae, A; Ichihara, E; Iwamoto, Y; Kiura, K; Maeda, Y; Nakasuka, T; Umeno, T	1
Cui, J; Li, Y; Liu, R; Qi, Q; Xu, L; Zhang, Y	1
Aisner, J; Burley, SK; Castellano, GM; Ganesan, S; Pine, SR; Vallat, B; Yu, HA	1
Chen, G; Li, XL; Lv, T; Song, Y; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W	1
Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK	1
Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y	1
Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J	1
Esumi, H; Goto, K; Ishii, G; Kohno, T; Makinoshima, H; Matsumoto, S; Matsushima, K; Mimaki, S; Ochiai, A; Shibata, T; Suzuki, A; Suzuki, M; Suzuki, Y; Tsuchihara, K; Tsuta, K; Yoh, K	1
Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H	1
Hou, YH; Pan, JB; Zhang, GJ	1
Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C	1
Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM	1
Lazarus, DR; Ost, DE	1
Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H	1
Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J	1
Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V	1
Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N	1
Hirsh, V; Lungershausen, J; Massey, D; Mok, TS; O'Byrne, KJ; Palmer, M; Schuler, M; Sequist, LV; Shahidi, M; Yamamoto, N; Yang, JC; Zazulina, V	1
Aurisicchio, L; Ciliberto, G; Coluccia, P; D'Andrilli, A; De Vitis, C; Fattore, L; Giovagnoli, MR; Luberto, L; Malpicci, D; Mancini, R; Marra, E; Normanno, N; Noto, A; Roscilli, G; Ruco, L	1
Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M	1
Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T	1
Langer, CJ	1
Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H	1
Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S	1
Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O	1
Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G	1
Ema, T; Enomoto, Y; Kawano, R	1
Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T	1
Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP	1
Cao, F; Fan, FT; Kang, XH; Wang, LF; Xu, ZY	1
Borczuk, AC; Siegelin, MD	1
Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A	1
Liu, XQ; Qiao, TK	1
Horn, L; Lammers, PE; Lovly, CM	1
Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL	1
Cinquini, M; De Braud, F; Garassino, MC; Gelsomino, F; Haspinger, ER; Torri, V	1
de Marinis, F; Passaro, A	1
Sequist, LV; Yang, JC	2
Cho, S; Choi, DL; Choi, HE; Jang, SJ; Lee, JY; Lee, KT; Rim, HK	1
Funakoshi, Y; Maeda, H; Takeuchi, Y	1
Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W	1
Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K	1
Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS	1
Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H	1
Guo, L; Li, M; Liu, Z; Meng, Q; Shi, L; Tang, J; Tao, H; Tong, L; Wu, H; Wu, W; Xu, L; Zhu, Y	1
Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E	1
Cai, G; Carbone, DP; de Stanchina, E; Gale, M; Gettinger, S; Horn, L; Jia, P; Miller, V; Nebhan, C; Pao, W; Pirazzoli, V; Politi, K; Shapiro, EM; Song, X; Stephens, PJ; Walther, Z; Wurtz, A; Yin, R; Zhao, Z	1
Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S	1
Leighl, NB; Zer, A	1
Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C	1
Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Sun, Y; Wang, H; Wang, Y; Wang, Z; Zhang, X	1
Costa, DB; Gandhi, L; Gerber, DE	1
Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X	1
Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L	1
Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M	1
Ho, CC; Kuo, YW; Lin, CH; Lin, MT	1
Imai, T; Ishigame, T; Kohno, T; Kumamoto, K; Saito, M; Tsuta, K	1
Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G	1
Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM	1
Chen, HW; Chen, WJ; Ho, CC; Ho, CL; Hsieh, WY; Lee, JY; Li, LH; Li, PR; Wang, CC; Wu, P; Yang, SM; Yen, MY	1
Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S	1
Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R	1
Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL	1
Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A	1
Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M	1
Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L	1
Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z	1
Bi, F; Ge, X; Huang, M; Wang, Y; Zheng, L	1
Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS	1
Goto, K; Hashimoto, H; Iida, S; Ishii, G; Matsumoto, S; Nagai, K; Neri, S; Niho, S; Niimi, A; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T	1
Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q	1
Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X	1
Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G	1
Balikó, Z; Sárosi, V	1
Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H	1
Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H	1
Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB	1
Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M	1
Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D	1
Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H	1
Canon, JL; Chand, VK; De Grève, J; Decoster, L; Galdermans, D; Graas, MP; Massey, D; Moran, T; Schallier, D; Teugels, E; Vansteenkiste, J; Vuylsteke, P	1
Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ	1
Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA	1
Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y	1
Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C	1
Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H	1
Gemma, A; Kitamura, K; Kosaihira, S; Kubota, K; Matsuda, K; Matsumoto, M; Minegishi, Y; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T; Yoshimura, A; Zou, F	1
Kohno, T; Makinoshima, H; Matsushima, K; Sugano, S; Suzuki, A; Suzuki, Y; Tsuchihara, K	1
Amato, E; Bria, E; Brunelli, M; Chilosi, M; Corbo, V; Fassan, M; Giglioli, E; Kinspergher, S; Milella, M; Novello, S; Peretti, U; Pilotto, S; Righi, L; Santo, A; Scarpa, A; Sperduti, I; Tortora, G; Vavalà, T	1
Hu, C; Li, M; Wang, Q	1
Hida, T; Kato, T; Kiura, K; Massey, D; Okamoto, I; Seki, Y; Seto, T; Yamamoto, N; Yokoyama, A; Yoshioka, H	1
Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ	1
Gow, CH; Liao, WY; Liu, YN; Shih, JY	1
Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S	1
Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB	1
Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL	1
Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L	1
Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG	1
Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X	1
Liu, G; Liu, H; Ma, T; Zhang, X	1
Chen, CS; Chen, CY; Chen, JJ; Hong, TM; Hsiao, TH; Huang, KY; Kao, SH; Salunke, SB; Su, KY; Wang, WL; Yang, PC; Yang, SC	1
Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M	1
Chen, Z; Wu, JH; Zhang, X; Zhao, J	1
Du, LW; Feng, JG; Jiang, H; Li, JH; Ma, SL; Song, SC; Zhao, PJ; Zhou, GH; Zhu, XH	1
Chang, YL; Liu, YN; Shih, JY; Tsai, MF; Wen, YF; Wu, SG; Yang, JC; Yang, PC; Yu, CJ	1
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W	1
Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y	1
Chen, L; Li, Q; Peng, S; Wang, R; Wang, W; Yang, H	1
Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K	1
Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM	1
Chen, C; Lian, ZZ; Sun, YF	1
Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H	1
Arrieta, O; Astudillo-de la Vega, H; Caballe-Perez, E; Cruz-Rico, G; Macedo-Pérez, EO; Martinez-Alvarez, I; Martínez-Hernández, JN; Ramírez-Tirado, LA; Soca-Chafre, G; Soto-Perez-de-Celis, E	1
Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H	1
Contreras-Díaz, M; López-Herrero, F; Martínez-Bernal, G; Medina-Tapia, A; Molina-Socola, FE; Rueda-Rueda, T; Sánchez-Vicente, JL	1
Cho, E; Han, H; Han, JY; Jung, J; Kim, HY; Kim, SW; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Min, YJ; Nam, BH	1
Gong, J; Hu, P; Sun, S; Tang, F; Wang, Y; Wang, Z; Xie, C	1
Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP	1
Chang, GC; Close, S; Garrus, JE; Geater, SL; Han, M; Komarnitsky, P; Mok, TS; Park, K; Payumo, F; Su, WC; Tan, EH; Yang, JC	1
Creighton, CJ; Deng, B; Gibbons, DL; Guo, L; Lu, Q; Molina, JR; Sun, Z; Yang, P; Yang, Y; Yi, ES; Zhang, T	1
Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yukawa, T	1
Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A	1
Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J	1
Dickgreber, N; Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Sequist, LV; Shah, R; Wind, S; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C	1
Arata, S; Hirose, T; Ishida, H; Kishino, Y; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Shirai, T; Yamaoka, T	1
Nakamura, H; Nishimura, T	1
Doki, Y; Fukuoka, J; Hori, T; Isobe, M; Kurose, K; Nakayama, E; Nishio, Y; Nozawa, R; Ohue, Y; Oka, M; Tanaka, T	1
Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N	1
Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A	1
Feng, J; Gibson, N; Hirsh, V; Hou, M; Hu, CP; Huang, Y; Kim, M; Li, W; Lu, S; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC	1
Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G	1
Bashir, ES; Chan, CY; Kwan, AK; Mun Keong, K	1
Chang, CH; Lee, CH; Wang, JY	1
Akamatsu, H; Azuma, K; Fukuhara, T; Goto, K; Harada, D; Harada, T; Hotta, K; Iwama, E; Kishimoto, J; Kurata, T; Nakanishi, Y; Nishio, K; Nosaki, K; Ohyanagi, F; Okamoto, I; Sakai, K; Shimose, T	1
Ando, K; Arata, S; Ishida, H; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Yamaoka, T	1
Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S	1
Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE	1
Lam, KC; Mok, TS	1
Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y	1
Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M	1
Asamura, H; Furuta, K; Kohno, T; Kozu, Y; Sekine, I; Suzuki, K; Tamura, T; Tsuda, H; Tsuta, K; Watanabe, S; Yokota, J; Yoshida, A	1
Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L	1
Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K	1
Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA	1
Han, JH; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, YJ; Park, JH; Yoon, KA; Yoon, SJ; Yun, T	1
Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K	1
Morio, A; Ninomiya, H; Sunada, K	1
Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A	1
Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L	1
Wang, L; Xiao, F; Zhang, W; Zheng, J	1
Antoine, M; Brambilla, E; Busser, B; Cadranel, J; Coll, JL; de Fraipont, F; Dufort, S; Hurbin, A; Moro-Sibilot, D; Rabbe, N; Tenaud, C; Wislez, M	1
Li, Y; Liu, B; Qin, X; You, J; Zhou, Q	1
Gu, A; Han, B; Shen, J; Shi, C; Xiong, L	1
Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M	1
Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Yoon, KA; Yun, T	1
Shepherd, FA	1
Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC	1
Chanprapaph, K; Pongcharoen, P; Vachiramon, V	1
Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL	1
Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C	1
de Lima Lopes, G; Do, YK; Finkelstein, EA; Mok, T; Segel, JE; Tan, DS	1
Jou, YS; Ko, JY; Lin, KT; Lin, SC; Tu, PH; Wang, YW	1
Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q	1
Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z	1
He, CS; Hu, ZH; Liu, JL; Tian, Y; Xie, M; Xu, F; Zhang, L; Zhao, LP	1
Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B	1
Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X	1
Asaka, R; Hamanaka, W; Hatano, S; Ishikawa, Y; Lim Choi, Y; Mano, H; Nakagawa, K; Ninomiya, H; Okumura, S; Sakata, S; Satoh, Y; Soda, M; Suzuki, R; Takeuchi, K; Togashi, Y; Uehara, H	1
Arai, Y; Chiku, S; Enari, M; Furuta, K; Harris, CC; Haugen, A; Hiramoto, M; Ichikawa, H; Iwakawa, R; Kohno, T; Nammo, T; Ogawa, S; Ogiwara, H; Oike, T; Okayama, H; Sakamoto, H; Schetter, AJ; Sekine, I; Shibata, T; Shimada, Y; Skaug, V; Totoki, Y; Tsuda, H; Tsuta, K; Watanabe, S; Yamanaka, I; Yasuda, K; Yokota, J; Yoshida, T	1
Chen, W; Hu, CP; Liu, JK; Lu, RL; Xiong, Z; Zhou, H; Zhou, ML	1
Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y	1
Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H	1
Guo, L; Liu, Z; Meng, Q; Shi, H; Tang, J; Xu, L; Zhu, Y	1
Atagi, S; Fukuoka, M; Ichinose, Y; Ishikura, S; Niho, S; Ohe, Y; Okamoto, H; Saijo, N; Shibata, T; Takeda, K; Tamura, T; Yokoyama, A	1
Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J	1
Liu, G; Wang, W; Zhang, X; Zhu, X	1
Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X	1
Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE	1
Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N	1
Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP	1
Ikari, A; Sato, T; Sugatani, J; Watanabe, R; Yamazaki, Y	1
Juergens, R; Levine, MN	1
Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X	1
Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA	1
Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M	1
Gerber, DE; Hamann, HA; Lee, SJ; Rasco, DW; Woodruff, S	1
Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N	1
Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D	1
Chen, YG; Chian, CF; Lin, CS; Shen, CH	1
Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M	1
Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL	1
Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T	1
Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX	1
Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L	1
Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W	1
Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z	1
Chua, KT; Lee, CH; Liam, CK; Lim, BK; Pang, YK; Ruthranesan, M	1
Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C	1
Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S	1
Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K	1
Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK	1
Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ	1
Hashisako, M; Ikegame, S; Kajiki, A; Kumazoe, H; Nagata, N; Wakamatsu, K	1
Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y	1
Cho, YW; Choi, HW; Choi, IS; Choi, JH; Lee, HW; Lee, JY; Lee, KT; Park, JY; Rim, HK	1
Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H	1
Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y	1
Jeon, WI; Lee, SY; Ryu, PD	1
Wang, B; Wang, YN; Zhao, Q	1
Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S	1
Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N	1

Reviews

12 review(s) available for quinazolines and Lung Adenocarcinoma

Article	Year
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an The oncologist, 2019, Volume: 24, Issue:8 Topics: Adenocarcinoma of Lung; Adult; Chemotherapy, Adjuvant; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Oncogene Proteins, Fusion; Pneumonectomy; Precision Medicine; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; Thoracoscopy; Treatment Outcome	2019
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature]. Revue de pneumologie clinique, 2013, Volume: 69, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms	2013
How and when to use genetic markers for nonsmall cell lung cancer. Current opinion in pulmonary medicine, 2013, Volume: 19, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases	2013
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. International journal of cancer, 2013, Nov-15, Volume: 133, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2013
Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction	2014
[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014, Volume: 17, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Stomatitis	2014
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jun-20, Volume: 32, Issue:18 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure	2014
Management and future directions in non-small cell lung cancer with known activating mutations. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases	2014
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature. Medicine, 2016, Volume: 95, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma	2016
Targeted therapy: an evolving world of lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2011
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases	2011
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines	2012

Trials

38 trial(s) available for quinazolines and Lung Adenocarcinoma

Article	Year
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). International journal of clinical oncology, 2023, Volume: 28, Issue:1 Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2023
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. International journal of cancer, 2017, 09-15, Volume: 141, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines	2017
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. Lung cancer (Amsterdam, Netherlands), 2019, Volume: 133 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis	2019
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome	2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Quinazolines	2013
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2013
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome	2013
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome	2013
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer, 2014, May-01, Volume: 120, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines	2014
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome	2014
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma]. Zhonghua yi xue za zhi, 2014, Aug-13, Volume: 94, Issue:30 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking	2014
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. Journal of cancer research and therapeutics, 2014, Volume: 10 Suppl Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis	2014
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome	2014
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies. International journal of oncology, 2015, Volume: 46, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine	2015
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. Medicine, 2015, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome	2015
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2015
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2015
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer science, 2015, Volume: 106, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines	2015
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Mar-16, Volume: 16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult	2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-20, Volume: 34, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines	2016
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. Targeted oncology, 2016, Volume: 11, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome	2016
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ( Cancer research and treatment, 2017, Volume: 49, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment	2017
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines	2016
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting. Talanta, 2016, Nov-01, Volume: 160 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea	2016
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British journal of cancer, 2017, Jan-17, Volume: 116, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines	2017
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Targeted oncology, 2010, Volume: 5, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay	2010
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome	2011
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of pathology, 2011, Volume: 225, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Proteins; Quinazolines; Receptor, IGF Type 1; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured	2011
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure	2011
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell-Free System; DNA; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Smoking; Treatment Outcome	2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome	2011
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer, 2012, Feb-15, Volume: 118, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Cost-Benefit Analysis; ErbB Receptors; Gefitinib; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Pharmacogenetics; Quality-Adjusted Life Years; Quinazolines; Singapore; Treatment Outcome	2012
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumonia; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine	2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking	2012
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult	2012
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines	2012
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur	2013

Other Studies

225 other study(ies) available for quinazolines and Lung Adenocarcinoma

Article	Year
BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level. Experimental & molecular medicine, 2021, Volume: 53, Issue:12 Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Adenocarcinoma of Lung; Apoptosis; Azepines; Biomarkers; Cell Line, Tumor; Citric Acid Cycle; Disease Susceptibility; Drug Resistance, Neoplasm; Energy Metabolism; ErbB Receptors; Histone Demethylases; Humans; Immunohistochemistry; Mitochondria; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2021
EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma. Current molecular pharmacology, 2023, Volume: 16, Issue:2 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines	2023
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. Scientific reports, 2022, 04-29, Volume: 12, Issue:1 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines	2022
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report. Medicine, 2022, Aug-19, Volume: 101, Issue:33 Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines	2022
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma. Immunotherapy, 2022, Volume: 14, Issue:16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines	2022
A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma. CEN case reports, 2023, Volume: 12, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Glomerulonephritis; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis	2023
[Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Octogenarians; Quinazolines	2023
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. The Kaohsiung journal of medical sciences, 2023, Volume: 39, Issue:7 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species	2023
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation. Investigational new drugs, 2023, Volume: 41, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2023
Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma. Biochemical and biophysical research communications, 2023, 11-19, Volume: 682 Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2023
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations. Lung cancer (Amsterdam, Netherlands), 2019, Volume: 136 Topics: Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Structure-Activity Relationship; Treatment Outcome	2019
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific journal of cancer prevention : APJCP, 2019, 08-01, Volume: 20, Issue:8 Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate	2019
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Quinolines	2019
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study. The Journal of international medical research, 2020, Volume: 48, Issue:8 Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis	2020
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation. Investigational new drugs, 2021, Volume: 39, Issue:5 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2021
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report. Tumori, 2021, Volume: 107, Issue:6 Topics: Adenocarcinoma of Lung; Carcinoma, Adenosquamous; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines	2021
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2019, Nov-12, Volume: 34, Issue:4 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome	2019
HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib. Annals of palliative medicine, 2022, Volume: 11, Issue:4 Topics: Adenocarcinoma of Lung; Bevacizumab; Exons; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutagenesis, Insertional; Quinazolines	2022
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine	2017
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction	2017
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer science, 2017, Volume: 108, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays	2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC pharmacology & toxicology, 2017, 05-10, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy	2017
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Gene Fusion; Humans; Lung Neoplasms; Male; Middle Aged; Neuregulin-1; Quinazolines	2017
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 108 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Exons; Female; Humans; INDEL Mutation; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2017
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 110 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome	2017
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome	2017
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. Internal medicine (Tokyo, Japan), 2017, Sep-01, Volume: 56, Issue:17 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome	2017
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Medicine, 2017, Volume: 96, Issue:33 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines	2017
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure. Journal of visualized experiments : JoVE, 2017, 08-11, Issue:126 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfones	2017
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. Internal medicine (Tokyo, Japan), 2017, Nov-01, Volume: 56, Issue:21 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines	2017
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Dec-01, Volume: 28, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Neuregulin-1; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Syndecan-4	2017
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Experimental cell research, 2017, 12-15, Volume: 361, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones	2017
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. AJR. American journal of roentgenology, 2018, Volume: 210, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult	2018
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer biology & therapy, 2017, Dec-02, Volume: 18, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma	2017
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Female; Humans; Lung Neoplasms; Middle Aged; Neuregulin-1; Quinazolines; Radiation-Sensitizing Agents	2017
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert review of anticancer therapy, 2018, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2018
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations. Internal medicine (Tokyo, Japan), 2018, Apr-01, Volume: 57, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome	2018
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC pharmacology & toxicology, 2017, 12-13, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2017
Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models. Biochimica et biophysica acta. Molecular cell research, 2018, Volume: 1865, Issue:3 Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Claudin-2; Doxorubicin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Quinazolines; Spheroids, Cellular	2018
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report. Experimental oncology, 2017, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed	2017
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival. Asia-Pacific journal of clinical oncology, 2018, Volume: 14 Suppl 1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Survival Analysis; Time Factors	2018
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 118 Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cohort Studies; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis	2018
Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thoracic cancer, 2018, Volume: 9, Issue:5 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines	2018
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma. International journal of nanomedicine, 2018, Volume: 13 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results	2018
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report. Medicine, 2018, Volume: 97, Issue:15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid	2018
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine, 2018, Volume: 97, Issue:18 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma	2018
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncology reports, 2018, Volume: 40, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A	2018
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest. Respiratory research, 2018, 05-21, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines	2018
[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018, Jun-20, Volume: 21, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Oxidoreductases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines	2018
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 47, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin	2018
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts. Thoracic cancer, 2018, Volume: 9, Issue:9 Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Mice; Mutation; Pemetrexed; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays	2018
Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and cell biology, 2018, Volume: 37, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Telomere	2018
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clinical lung cancer, 2019, Volume: 20, Issue:1 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis	2019
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. Internal medicine (Tokyo, Japan), 2019, Volume: 58, Issue:1 Topics: Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Quinazolines; Sequence Deletion	2019
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. BMC cancer, 2019, Feb-08, Volume: 19, Issue:1 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Alleles; Amino Acid Substitution; Aniline Compounds; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Crown Ethers; ErbB Receptors; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Tomography, X-Ray Computed; Treatment Outcome	2019
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway. Journal of experimental & clinical cancer research : CR, 2019, Feb-21, Volume: 38, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation	2019
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report. Medicine, 2019, Volume: 98, Issue:18 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines	2019
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines. International journal of molecular medicine, 2019, Volume: 44, Issue:2 Topics: Adenocarcinoma of Lung; Anthraquinones; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2019
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Japanese journal of clinical oncology, 2019, Aug-01, Volume: 49, Issue:8 Topics: Adenocarcinoma of Lung; Afatinib; Aged; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome	2019
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tumor Stem Cell Assay	2019
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:8 Topics: Adenocarcinoma of Lung; Crown Ethers; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Quinazolines	2019
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma. Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines	2013
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer science, 2013, Volume: 104, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Down-Regulation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; RNA, Messenger; Signal Transduction; Transcriptome	2013
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines	2013
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases	2013
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction	2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome	2013
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget, 2013, Volume: 4, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays	2013
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines	2013
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome	2013
Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines	2013
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy	2013
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. International journal of oncology, 2013, Volume: 43, Issue:6 Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays	2013
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform The Journal of molecular diagnostics : JMD, 2014, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA	2014
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines	2013
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib. Journal of Korean medical science, 2013, Volume: 28, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome	2013
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Pathology oncology research : POR, 2014, Volume: 20, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult	2014
[Tumor microenvironment elicits primary resistance to afatinib through HGF secretion]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Microenvironment; Vimentin	2013
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-20, Volume: 32, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents	2013
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines	2014
Afatinib-related nonhematologic adverse events: is common evaluation enough for now? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines	2014
Reply to F. De Marinis et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines	2014
Reply to E.R. Haspinger et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines	2014
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist. Bioorganic & medicinal chemistry letters, 2014, Mar-15, Volume: 24, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Lung Neoplasms; Piperazines; Quinazolines	2014
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma. Asian cardiovascular & thoracic annals, 2013, Volume: 21, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2013
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochemical and biophysical research communications, 2014, Mar-28, Volume: 446, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm	2014
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia. BMJ case reports, 2014, Mar-13, Volume: 2014 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines	2014
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome	2014
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. The Journal of pathology, 2014, Volume: 234, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines	2014
Case of erlotinib-induced photosensitivity. The Journal of dermatology, 2014, Volume: 41, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines	2014
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell reports, 2014, May-22, Volume: 7, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Mice, Transgenic; Multiprotein Complexes; Mutation; Quinazolines; Random Allocation; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2014
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. Cancer biology & therapy, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2	2014
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Oncology reports, 2014, Volume: 32, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines	2014
[Efficacy of gefitinib for young patients with unknown EGFR gene mutation  in advanced lung adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014, Volume: 17, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2014
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2014
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Targeted oncology, 2015, Volume: 10, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry	2015
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain; Cetuximab; ErbB Receptors; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Meningeal Neoplasms; Mutation; Neoplasms, Second Primary; Quinazolines	2014
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis, 2014, Volume: 35, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinogenesis; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines	2014
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer cell, 2014, Aug-11, Volume: 26, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2014
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome	2014
Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PloS one, 2014, Volume: 9, Issue:8 Topics: Acridine Orange; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antineoplastic Agents, Phytogenic; Autophagy; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cupressaceae; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Gas Chromatography-Mass Spectrometry; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Monoterpenes; Oils, Volatile; Quinazolines; Real-Time Polymerase Chain Reaction; Taiwan; Tropolone; Tumor Stem Cell Assay	2014
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome	2014
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis	2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. PloS one, 2014, Volume: 9, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome	2014
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction	2014
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. Oncotarget, 2014, Sep-30, Volume: 5, Issue:18 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2014
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report. Journal of medical case reports, 2014, Oct-09, Volume: 8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous	2014
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells. Molecular medicine reports, 2014, Volume: 10, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines	2014
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Molecular medicine reports, 2015, Volume: 11, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results	2015
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer. The Korean journal of internal medicine, 2014, Volume: 29, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome	2014
Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Feb-01, Volume: 21, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblasts; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mutation; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Risk Factors; Treatment Outcome; Tumor Microenvironment	2015
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. Proteomics, 2015, Volume: 15, Issue:2-3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction	2015
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma]. Magyar onkologia, 2014, Volume: 58, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome	2014
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines	2014
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung? APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA	2015
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer research, 2015, Mar-15, Volume: 75, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction	2015
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report. Tumori, 2015, Apr-28, Volume: 101, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome	2015
Disease flare after gefitinib discontinuation. Respiratory investigation, 2015, Volume: 53, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment	2015
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature communications, 2015, Mar-11, Volume: 6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides	2015
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines	2015
Current two EGFR mutations in lung adenocarcinoma - case report. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2015, Volume: 28, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography	2015
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC cancer, 2015, Feb-06, Volume: 15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines	2015
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome biology, 2015, Apr-03, Volume: 16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cytoskeletal Proteins; Drug Delivery Systems; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Essential; Humans; Lung Neoplasms; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; RNA; Sequence Analysis, RNA; Single-Cell Analysis; Transcriptome	2015
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget, 2015, May-20, Volume: 6, Issue:14 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Proportional Hazards Models; Quinazolines; Sequence Analysis, DNA	2015
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Volume: 18, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines	2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-01, Volume: 33, Issue:22 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation	2015
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine	2015
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting	2015
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicology and applied pharmacology, 2015, Nov-01, Volume: 288, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2015
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays	2015
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines	2016
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Sep-20, Volume: 18, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2015
[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation and Apoptosis of Lung Adenocarcinoma Cell H1975]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Oct-20, Volume: 18, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Epoxy Compounds; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phenanthrenes; Protein Kinase Inhibitors; Quinazolines	2015
Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation. American journal of respiratory and critical care medicine, 2016, Apr-01, Volume: 193, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Enzyme Assays; ErbB Receptors; Humans; Lung Neoplasms; Mass Spectrometry; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome	2016
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma. Medicine, 2016, Volume: 95, Issue:2 Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome	2016
Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest. Molecular medicine reports, 2016, Volume: 13, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Saponins	2016
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget, 2016, Mar-15, Volume: 7, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Signal Transduction	2016
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Volume: 38, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2016
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR. Oncotarget, 2016, Mar-29, Volume: 7, Issue:13 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines	2016
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. International journal of oncology, 2016, Volume: 48, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta	2016
Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance. Chinese medical journal, 2016, Apr-05, Volume: 129, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Female; Fever; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nivolumab; Quinazolines	2016
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. The journal of medical investigation : JMI, 2016, Volume: 63, Issue:1-2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed	2016
Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib. Archivos de la Sociedad Espanola de Oftalmologia, 2016, Volume: 91, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Signal Transduction	2016
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncology reports, 2016, Volume: 36, Issue:1 Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2016
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 107 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases	2017
A genetic cell context-dependent role for ZEB1 in lung cancer. Nature communications, 2016, 07-26, Volume: 7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-3; Receptor, Notch1; Reproducibility of Results; Smoking; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1	2016
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report. World journal of surgical oncology, 2016, Jun-29, Volume: 14, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed	2016
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:17 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines	2016
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular cancer therapeutics, 2016, Volume: 15, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, IGF Type 1; Receptors, Death Domain; Receptors, Somatomedin; Signal Transduction; Smad2 Protein; Smad3 Protein; Somatomedins	2016
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations. Advances in experimental medicine and biology, 2016, Volume: 926 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People	2016
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. Cancer immunology research, 2016, Volume: 4, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antigens, Neoplasm; B7-H1 Antigen; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; ErbB Receptors; Galectins; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Quinazolines; Receptor, ErbB-2; Survival Analysis	2016
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene, 2017, 03-23, Volume: 36, Issue:12 Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3	2017
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy. Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents	2017
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 103 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases. Journal of orthopaedic surgery (Hong Kong), 2016, Volume: 24, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteogenesis; Pelvic Bones; Quinazolines; Spine	2016
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 04-20, Volume: 35, Issue:12 Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines	2017
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 01-01, Volume: 28, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Circulating Tumor DNA; ErbB Receptors; Female; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines	2017
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular cancer research : MCR, 2017, Volume: 15, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays	2017
Modulation of P-gp expression by lapatinib. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors	2011
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2	2010
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed	2011
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibody Specificity; ErbB Receptors; Female; Gefitinib; Genetic Association Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Point Mutation; Quinazolines; Sequence Deletion	2011
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integrative cancer therapies, 2011, Volume: 10, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2011
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer, 2011, Jul-15, Volume: 117, Issue:14 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Smoking; X-ray Repair Cross Complementing Protein 1	2011
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure	2011
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed	2011
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. Journal of proteomics, 2011, Jun-10, Volume: 74, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry	2011
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer research, 2011, Jul-01, Volume: 71, Issue:13 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous	2011
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids	2011
[Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2011
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines	2011
Molecular selection trumps clinical selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome	2011
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment. Archives of dermatology, 2011, Volume: 147, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines	2011
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. The European respiratory journal, 2012, Volume: 39, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA	2012
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays	2011
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Metastasis; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction	2011
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer cell, 2011, Sep-13, Volume: 20, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors	2011
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Oncology reports, 2012, Volume: 27, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome	2012
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of cellular biochemistry, 2012, Volume: 113, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay	2012
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion	2012
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome	2012
RET, ROS1 and ALK fusions in lung cancer. Nature medicine, 2012, Feb-12, Volume: 18, Issue:3 Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytoskeletal Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; Piperidines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors	2012
KIF5B-RET fusions in lung adenocarcinoma. Nature medicine, 2012, Feb-12, Volume: 18, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Animals; Cell Transformation, Neoplastic; ErbB Receptors; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Japan; Kinesins; Lung Neoplasms; Mice; NIH 3T3 Cells; Norway; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; United States	2012
[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT]. Zhonghua yi xue za zhi, 2011, Nov-01, Volume: 91, Issue:40 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cone-Beam Computed Tomography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome	2011
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy	2012
A case of choroidal metastasis of lung cancer successfully treated with erlotinib. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines	2012
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncology reports, 2012, Volume: 27, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines	2012
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids	2012
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta pharmacologica Sinica, 2012, Volume: 33, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors	2012
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome	2012
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines	2012
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 103, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured	2012
Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells. Biochimica et biophysica acta, 2012, Volume: 1823, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Binding Sites; Butadienes; Cell Line, Tumor; Claudins; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Nitriles; Promoter Regions, Genetic; Protease Inhibitors; Protein Binding; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transcription Factor AP-1; Tyrphostins	2012
Method to our madness or madness in our methods? Pitfalls in trial methodology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents	2012
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer discovery, 2011, Volume: 1, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins	2011
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed	2012
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. Patient education and counseling, 2012, Volume: 89, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comprehension; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Patient Preference; Perception; Qualitative Research; Quality of Life; Quinazolines; Texas; Treatment Outcome	2012
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation]. No shinkei geka. Neurological surgery, 2012, Volume: 40, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt	2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of clinical investigation, 2012, Volume: 122, Issue:7 Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays	2012
Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis	2012
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer science, 2012, Volume: 103, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2012
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window. Biomedical microdevices, 2012, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine	2012
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate	2012
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Molecular cancer therapeutics, 2012, Volume: 11, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4	2012
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clinical lung cancer, 2013, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry	2013
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration; international review of thoracic diseases, 2012, Volume: 84, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Malaysia; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2012
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine	2012
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer discovery, 2012, Volume: 2, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering	2012
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer research, 2012, Nov-15, Volume: 72, Issue:22 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors	2012
Survival of lung adenocarcinoma patients with malignant pleural effusion. The European respiratory journal, 2013, Volume: 41, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome	2013
Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. The Tohoku journal of experimental medicine, 2012, Volume: 228, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polyphosphates; Quinazolines; Radionuclide Imaging; Technetium Compounds; Tomography, X-Ray Computed; Treatment Outcome	2012
The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies	2012
T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells. Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Transplantation, Heterologous	2012
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2012
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World journal of surgical oncology, 2012, Nov-07, Volume: 10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2012
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells. Anticancer research, 2012, Volume: 32, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays	2012
Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2 Topics: Acneiform Eruptions; Adenocarcinoma; Adenocarcinoma of Lung; Antigens, CD1; Antineoplastic Agents; Biopsy; Blister; Chemotherapy, Adjuvant; Crown Ethers; Dose Fractionation, Radiation; Down-Regulation; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Face; Folliculitis; Humans; Immunohistochemistry; Ki-67 Antigen; Langerhans Cells; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thoracic Wall	2013
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2013